[{"id":"6ed5215e-5228-4ee7-8f80-16805303ee59","acronym":"","url":"https://clinicaltrials.gov/study/NCT03922880","created_at":"2021-01-18T19:17:57.870Z","updated_at":"2024-07-02T16:35:56.988Z","phase":"Phase 1","brief_title":"Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma","source_id_and_acronym":"NCT03922880","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" GNAQ • GNA11 • CYSLTR2 • PLCB4","pipe":"","alterations":" ","tags":["GNAQ • GNA11 • CYSLTR2 • PLCB4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Hepacid (pegargiminase)"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 04/16/2019","start_date":" 04/16/2019","primary_txt":" Primary completion: 01/20/2023","primary_completion_date":" 01/20/2023","study_txt":" Completion: 01/20/2023","study_completion_date":" 01/20/2023","last_update_posted":"2023-01-26"}]